CYTOMX THERAPEUTICS INC (CTMX)
US23284F1057 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 36.19M | 17.17M | 193.70M | 205.50M | 191.90M | |||
| Marketable Securities | 114.10M | 157.34M | 0.00 | 99.70M | 124.30M | |||
| Receivables | 13.18M | 3.43M | 36.00M | 800.00K | 800.00K | |||
| Other Current Assets | 3.79M | 5.00M | 7.50M | 4.30M | 7.10M | |||
| Total Current Assets | 167.25M | 182.94M | 237.10M | 310.30M | 324.00M | |||
| Non-Current Assets | ||||||||
| PPE Net | 14.80M | 16.18M | 21.00M | 25.30M | 29.40M | |||
| Goodwill | 949.00K | 949.00K | 900.00K | 900.00K | 900.00K | |||
| Intangibles | 693.00K | 729.00K | 900.00K | 1.00M | 1.20M | |||
| Other Non-Current Assets | 997.00K | 1.00M | 900.00K | 1.80M | 3.10M | |||
| Total Non-Current Assets | 17.44M | 18.86M | 23.80M | 29.10M | 34.70M | |||
| TOTAL ASSETS | 184.69M | 201.79M | 260.90M | 339.40M | 358.70M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | N/A | N/A | N/A | N/A | N/A | |||
| Accrued Expenses | 18.94M | 22.19M | 26.90M | 34.20M | 23.10M | |||
| Accounts Payable | 1.96M | 1.46M | 2.80M | 2.80M | 3.00M | |||
| Other Current Liabilities | 123.63M | 132.27M | 122.90M | 40.80M | 74.90M | |||
| Total Current Liabilities | 144.54M | 155.91M | 152.60M | 77.90M | 100.90M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Deferred Taxes/Income | N/A | N/A | N/A | N/A | N/A | |||
| Other Non-Current Liabilities | 71.83M | 93.33M | 194.00M | 262.00M | 207.90M | |||
| Total Non-Current Liabilities | 71.83M | 93.33M | 194.00M | 262.00M | 208.00M | |||
| TOTAL LIABILITIES | 216.37M | 249.24M | 346.60M | 339.90M | 308.90M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -709.66M | -723.45M | -722.90M | -623.60M | -450.10M | |||
| Additional Paid In Capital | 677.99M | 675.90M | 637.10M | 623.30M | 500.00M | |||
| Common Shares | 1.00K | 1.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -10.00K | 95.00K | 0.00 | -200.00K | 0.00 | |||
| Shares Outstanding | 68.14M | 67.31M | 66.20M | 65.40M | 48.30M | |||
| Tangible Book Value per Share | -0.49 | -0.73 | -1.32 | -0.04 | 0.99 | |||
| Total Shareholders' Equity | -31.68M | -47.45M | -85.80M | -500.00K | 49.80M | |||
| TOTAL LIABILITIES AND EQUITY | 184.69M | 201.79M | 260.90M | 339.40M | 358.70M | |||
| Statistics | ||||||||
| Debt/Equity | N/A | N/A | N/A | N/A | N/A | |||
| Current Ratio | 1.16 | 1.17 | 1.55 | 3.98 | 3.21 | |||
| Return On Assets (ROA) | 8.95% | -0.28% | -38.06% | -34.15% | -9.17% | |||
| Return On Equity (ROE) | N/A | N/A | N/A | N/A | -66.06% | |||
| Return On Invested Capital (ROIC) | 21.29% | N/A | N/A | N/A | N/A | |||
All data in USD